Strategic report Governance & remuneration Financial statements Investor information Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party Phase I Evaluation of clinical pharmacology, usually conducted in volunteers Also being developed for indications in another therapeutic area Phase II Determination of dose and initial evaluation of efcacy, conducted in a S Month of first submission small number of patients A Month of first regulatory approval for MAA, this is the first EU Phase III Large comparative study compound versus placebo and or established approval letter treatment in patients to establish clinical benefit and safety BLA Biological Licence Application MAA Marketing Authorisation Application Europe NDA New Drug Application USA MAA and NDA BLA regulatory review milestones shown in the table below are those that have been achieved.
Future ling dates are not included in this list.
Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Respiratory 2126458 phosphoinositide 3 kinase PI3K inhibitor idiopathic pulmonary brosis I 2256294 soluble epoxide hydrolase sEH inhibitor chronic obstructive pulmonary disease COPD I 2862277 tumour necrosis factor receptor-1 TNFR1 acute lung injury I domain antibody 961081 muscarinic acetylcholine antagonist, beta2 agonist COPD I uticasone furoate MABA glucocorticoid agonist 961081 MABA COPD II 2245035 toll-like receptor 7 agonist asthma II 2269557 PI3K inhibitor asthma & COPD II 2586881 recombinant human angiotensin converting acute lung injury II enzyme 2 danirixin CXCR2 chemokine receptor antagonistCOPD II uticasone furoate glucocorticoid agonist muscarinic acetylcholine asthma COPD overlap syndrome II umeclidinium antagonist losmapimod p38 kinase inhibitor oral COPD II mepolizumab IL5 monoclonal antibody nasal polyposis II uticasone furoate glucocorticoid agonist long-acting beta2 COPD III vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab IL5 monoclonal antibody COPD III Relvar Breo Ellipta long-acting beta2 agonist glucocorticoid agonist COPD mortality outcomes III vilanterol uticasone furoate vilanterol long-acting beta2 agonist COPD III mepolizumab IL5 monoclonal antibody severe eosinophilic asthma Submitted S: Nov14 S: Nov14 Anoro Ellipta muscarinic acetylcholine antagonist long-acting COPD Approved A: May14 A: Dec13 umeclidinium beta2 agonist vilanterol Arnuity Ellipta glucocorticoid agonist asthma Approved N A A: Aug14 uticasone furoate Incruse Ellipta muscarinic acetylcholine antagonist COPD Approved A: Apr14 A:Apr14 umeclidinium Relvar Breo Ellipta long-acting beta2 agonist glucocorticoid agonist asthma Approved A: Nov13 S: Jun14 vilanterol uticasone furoate Paediatric Vaccines RSV recombinant respiratory syncytial virus prophylaxis I maternal immunisation RSV recombinant viral vector respiratory syncytial virus prophylaxis I S. pneumoniae next recombinant conjugated Streptococcus pneumoniae disease prophylaxis II generation MMR live attenuated measles, mumps, rubella prophylaxis III US N A Mosquirix recombinant malaria prophylaxis Plasmodium falciparum Submitted S: Jun14 N A Malaria RTS, S DTPa-HBV-IPV Hib conjugated diphtheria, tetanus, pertussis, poliomyelitis, Approved N A hepatitis B, haemophilus inuenza II US Nimenrix conjugated Neisseria meningitis groups A, C, W & Y Approved A: Apr12 MenACWY-TT disease prophylaxis II US GSK Annual Report 2014 225 Strategic report Governance & remuneration Financial statements Investor information Pipeline, products and competition continued Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Other Vaccines Malaria next generation recombinant malaria prophylaxis Plasmodium falciparum II NTHi recombinant non-typeable Haemophilus inuenzae prophylaxis II Tuberculosis recombinant tuberculosis prophylaxis II Hepatitis C recombinant viral vector hepatitis C virus prophylaxis II Ebola recombinant viral vector prevention of lovirus haemorrhagic fevers caused III by Ebola Zaire virus Zoster recombinant Herpes Zoster prophylaxis III Antigen-Specic Cancer Immunotherapeutic MAGE-A3 recombinant treatment of melanoma III immunotherapeutic HIV ViiV Healthcare cabotegravir 1265744 HIV integrase inhibitor HIV infections II long-acting parenteral formulation cabotegravir 1265744 HIV integrase inhibitor HIV pre-exposure prophylaxis II long-acting parenteral formulation Triumeq dolutegravir HIV integrase inhibitor HIV infections xed dose combination Approved A: Sep14 A: Aug14 abacavir sulphate reverse transcriptase inhibitors lamivudine xed dose combination Oncology 525762 bromodomain inhibitor cancer I 2256098 focal adhesion kinase inhibitor cancer I 2636771 PI3K inhibitor cancer I 2816126 enhancer of zeste homologue2 EZH2 cancer I inhibitor 2849330 ErbB3 monoclonal antibody cancer I 2857916 beta cell maturation antigen antibody multiple myeloma I drug conjugate 2879552 lysine-specic demethylase 1 LSD1 cancer I inhibitor 3052230 broblast growth factor ligand trap cancer I afuresertib 2110183 AKT protein kinase inhibitor multiple myeloma I Votrient pazopanib multi-kinase angiogenesis inhibitor renal cell cancer I MK-3475 PD-1 monoclonal antibody afuresertib 2110183 AKT protein kinase inhibitor ovarian cancer II Mekinist trametinib MEK1 2 inhibitor BRAF protein non-small cell lung cancer II Tanlar dabrafenib kinase inhibitor Mekinist trametinib MEK1 2 inhibitor BRAF protein rare cancers II Tanlar dabrafenib kinase inhibitor Mekinist trametinib MEK1 2 inhibitor BRAF protein colorectal cancer II Tanlar dabrafenib kinase inhibitor human anti-EGFR panitumumab monoclonal antibody Revolade Promacta thrombopoietin receptor agonist acute myeloid leukaemia II eltrombopag Arzerra ofatumumab CD20 human monoclonal antibody chronic lymphocytic leukaemia, use in relapsed patients III Arzerra ofatumumab CD20 human monoclonal antibody follicular lymphoma refractory & relapsed patients III Mekinist trametinib MEK1 2 inhibitor BRAF protein metastatic melanoma, adjuvant therapy III Tanlar dabrafenib kinase inhibitor Revolade Promacta thrombopoietin receptor agonist myelodysplastic syndromes III eltrombopag Votrient pazopanib multi-kinase angiogenesis inhibitor renal cell cancer, adjuvant therapy III Arzerra ofatumumab CD20 human monoclonal antibody chronic lymphocytic leukaemia, first line therapy Approved A: Jun14 A: Apr14 Mekinist trametinib MEK1 2 inhibitor metastatic melanoma Approved A: Jul14 A: May13 Mekinist trametinib MEK1 2 inhibitor BRAF protein metastatic melanoma Approved A: Jan 14 Tanlar dabrafenib kinase inhibitor Revolade Promacta thrombopoietin receptor agonist aplastic anaemia Approved S: Nov14 A: Aug14 eltrombopag 226 GSK Annual Report 2014 Strategic report Governance & remuneration Financial statements Investor information Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Cardiovascular & Metabolic 1278863 prolyl hydroxylase inhibitor topical wound healing I 2798745 transient receptor potential cation heart failure I channel V4 TRPV4 antagonist 2881078 selective androgen receptor modulator muscle wasting I 1278863 prolyl hydroxylase inhibitor anaemia associated with chronic renal disease II 2330672 ileal bile acid transport inhibitor type 2 diabetes & cholestatic pruritus II camicinal motilin receptor agonist delayed gastric emptying II Eperzan Tanzeum GLP 1 agonist type 1 diabetes II albiglutide losmapimod p38 kinase inhibitor focal segmental glomerular sclerosis II otelixizumab CD3 monoclonal antibody new onset type 1 diabetes II losmapimod p38 kinase inhibitor acute coronary syndrome III retosiban oxytocin antagonist threatened pre-term labour III Eperzan Tanzeum GLP 1 agonist type 2 diabetes Approved A: Mar14 A:Apr14 albiglutide Immuno-inammation 2618960 IL7 receptor monoclonal antibody autoimmune disease I 2646264 spleen tyrosine kinase Syk inhibitor chronic urticaria I topical 2831781 LAG3 monoclonal antibody autoimmune disease I 2982772 RIP1 kinase inhibitor autoimmune disease I 3050002 CCL20 monoclonal antibody autoimmune disease I 3117391 macrophage targeted histone rheumatoid arthritis I deacetylase inhibitor 3196165 MOR103 granulocyte macrophage colonyrheumatoid arthritis II stimulating factor monoclonal antibody Benlysta belimumab B lymphocyte stimulator monoclonal transplant rejection II antibody i. v. Benlysta belimumab B lymphocyte stimulator monoclonal systemic lupus erythematosus III antibody s. c. Benlysta belimumab B lymphocyte stimulator monoclonal vasculitis III antibody i. v. sirukumab IL6 human monoclonal antibody s. c. rheumatoid arthritis III Rare Diseases 2398852 SAP monoclonal antibody amyloidosis I 23156898 SAP depleter CPHPC 2696274 ex-vivo stem cell gene therapy metachromatic leukodystrophy II 2696275 ex-vivo stem cell gene therapy Wiscott-Aldrich syndrome II ozanezumab neurite outgrowth inhibitor NOGO-A amyotrophic lateral sclerosis II monoclonal antibody 2696273 ex-vivo stem cell gene therapy adenosine deaminase severe combined immune III deficiency ADA-SCID mepolizumab IL5 monoclonal antibody s. c. eosinophilic granulomatosis with polyangiitis III Volibris ambrisentan endothelin A antagonist chronic thromboembolic pulmonary hypertension III Infectious Diseases 2838232 antiviral maturation inhibitor HIV infections I 2878175 NS5B polymerase inhibitor hepatitis C I 2140944 type 2 topoisomerase inhibitor bacterial infections II tafenoquine 8-aminoquinoline Plasmodium vivax malaria III Relenza i. v. zanamivir neuraminidase inhibitor i. v. inuenza III Neurosciences ofatumumab CD20 human monoclonal antibody s. c. neuromyelitis optica II Benlysta belimumab B lymphocyte stimulator monoclonal myaesthenia gravis II antibody i. v. ofatumumab CD20 human monoclonal antibody s. c. multiple sclerosis II rilapladib Lp-PLA2 inhibitor Alzheimer's disease II GSK Annual Report 2014 227 Strategic report Governance & remuneration Financial statements Investor information Pipeline, products and competition continued Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Ophthalmology 933776 beta amyloid monoclonal antibody geographic retinal atrophy II Dermatology 1940029 stearoyl CoA desaturase 1 inhibitor topical acne vulgaris I umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis I non-steroidal anti-inammatory atopic dermatitis & psoriasis II 2894512 chlorhexidine cationic polybiguanide topical umbilical cord care III CD20 human monoclonal antibody s. c. pemphigus vulgaris III ofatumumab Toctino alitretinoin retinoic acid receptor modulator chronic hand eczema III N A Brand names appearing in italics are trade marks either owned by and or licensed to GSK or associated companies.
Option-based alliances with third parties that include assets in phase I and phase III development: Company Disease Area Phase Adaptimmune cancer I Cancer Research UK cancer I ISIS Pharmaceuticals hepatitis B I  amyloidosis III OncoMed Pharmaceuticals oncology I oncology II Shionogi bacterial infection I 228 GSK Annual Report 2014
